摘要
目的观察过敏原检测CAP系统检测的过筛项目在过敏性鼻炎诊疗中的临床意义。方法用PharmaciaUniCAP100系统对86例过敏性鼻炎患者进行血清嗜酸细胞阳离子蛋白（ECP）、总IgE、吸入性变应原Phadiatop和食物性变应原fx5E测定,并选定20例非过敏性鼻炎患者作对照。结果过敏性鼻炎组血清ECP升高（〉15μg/L）者65例,占75.6%,对照组血清ECP升高者1例,占5.0%。总IgE升高（〉120kU/L）者80例,占93.0%,对照组血清总IgE升高者2例,占10.0%;Phadiatop阳性者76例,占88.4%,对照组3例,占15.0%。Phadiatop阳性中,D1阳性70例,D2阳性74例,H1阳性70例,分别占81.4%、97.4%和92.1%,有67.2%的患者血清有2种及以上的过敏原呈阳性反应,提示存在多种过敏原综合致敏的情况。fx5E阳性仅2例,占2.3%,对照组则阴性。结论用CAP变应原检测系统是一种可用于筛查和寻找过敏性鼻炎过敏原的体外检测手段,可为过敏性鼻炎预防、诊断和治疗提供依据。
Objective To explore the clinical significance of sieving detection with CAP anaphylactogen detection system in the diagnosis and treatment of allergic rhinitis. Methods Pharmacia UniCAP 100 system was applied to determining serum eosinophil cationic protein （ECP）, total IgE, inhalant allergen Phadiatop and cibarian allergen fxSE in 86 patients with allergic rhinitis and 20 controls. Results Serum ECP increased （〉15 μg/L） in 65 allergic rhinitis patients （65/86, 75. 60% and 1 healthy control （1/20, 50%）. Total IgE increased （〉120 kU/L） in 80 allergic rhinitis patients （80/ 86, 93.0%） and 2 healthy controls （2/20, 10%）. 76 atients in allergic rhinitis group were positive （76/86, 88.4%）, and 3 subjects in control group were Phadiatop positive （3/20, 15.0%）. In Phadiatop positive cases, 70 cases were D1 positive （81.40%）, 74 were D2 positive （97.4%）, and 70 were H1 positive （92.1%）. 67.2% of patients were two or above two kinds of serum allergens positive, indicating more than one kind of allergen sensibilization. Only 2 patients were fxSE positive （2.3%）, while all controls were fxSE negative. Conclusion CAP anaphylaetogen detection system is an available mean in sieving and seeking for allergens for allergic rhinitis in vitro, may provide a basis for the precaution, dignosis and treatment of allergic rhinitis.
出处
《国际检验医学杂志》
CAS
2007年第7期588-590,共3页
International Journal of Laboratory Medicine
